{"id":11480,"date":"2024-04-29T19:30:00","date_gmt":"2024-04-29T17:30:00","guid":{"rendered":"https:\/\/irlab.se\/mfn_news\/irlab-publicerar-arsredovisning-for-2023\/"},"modified":"2024-04-29T19:30:00","modified_gmt":"2024-04-29T17:30:00","slug":"irlab-publicerar-arsredovisning-for-2023","status":"publish","type":"mfn_news","link":"https:\/\/irlab.se\/sv\/mfn_news\/irlab-publicerar-arsredovisning-for-2023\/","title":{"rendered":"IRLAB publicerar \u00e5rsredovisning f\u00f6r 2023"},"content":{"rendered":"<div class=\"mfn-preamble\">\n<p><strong>G\u00f6teborg, den 29 april 2024 \u2013 IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), ett f\u00f6retag som uppt\u00e4cker och utvecklar nya behandlingar vid Parkinsons sjukdom, meddelade idag att bolagets \u00e5rsredovisning f\u00f6r 2023 finns tillg\u00e4nglig p\u00e5 bolags webbplats, www.irlab.se.<\/strong><\/p>\n<\/div>\n<div class=\"mfn-body\">\n<p>IRLAB har idag publicerat \u00e5rsredovisning 2023 f\u00f6r r\u00e4kenskaps\u00e5ret 1 januari till 31 december 2023. \u00c5rsredovisningen finns tillg\u00e4nglig p\u00e5 bolagets hemsida:\u00a0<a href=\"https:\/\/irlab.se\/sv\/investerare\/financial-reports\/\" rel=\"noopener\" target=\"_blank\">Finansiella rapporter \u2013 IRLAB<\/a>. <\/p>\n<p>En tryckt version av \u00e5rsredovisningen 2023 kommer finnas tillg\u00e4nglig fr\u00e5n och med slutet av maj.<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-79fce04a0668\">\n<p><strong class=\"mfn-heading-1\">F\u00f6r mer information<\/strong><\/p>\n<hr \/>\n<p>Gunnar Olsson, VD<br \/>Tel: +46 70 576 14 02<br \/>E-post: <a href=\"mailto:gunnar.olsson@irlab.se\" rel=\"noopener\" target=\"_blank\">gunnar.olsson@irlab.se<\/a><\/p>\n<p>Viktor Siewertz, CFO<br \/>Tel: +46 727 10 70 70<br \/>E-post:\u00a0<a href=\"mailto:viktor.siewertz@irlab.se\" rel=\"noopener\" target=\"_blank\">viktor.siewertz@irlab.se<\/a><\/p>\n<\/div>\n<div class=\"mfn-footer mfn-regulatory mfn-regulatory-vpml\">\n<p><em>Denna information \u00e4r s\u00e5dan information som IRLAB Therapeutics \u00e4r skyldigt att offentligg\u00f6ra enligt lagen om v\u00e4rdepappersmarknaden. Informationen l\u00e4mnades, genom ovanst\u00e5ende kontaktpersoners f\u00f6rsorg, f\u00f6r offentligg\u00f6rande den 2024-04-29 19:30 CEST.<\/em><\/p>\n<\/div>\n<div class=\"mfn-footer mfn-about mfn-a19a8f82b785\">\n<p><strong class=\"mfn-heading-1\">Om IRLAB<\/strong><\/p>\n<hr \/>\n<p>IRLAB uppt\u00e4cker och utvecklar en portf\u00f6lj av transformativa behandlingar f\u00f6r alla stadier av Parkinsons sjukdom. Bolaget har sitt ursprung i Nobelpristagaren Prof. Arvid Carlssons forskargrupp och uppt\u00e4ckten av ett samband mellan hj\u00e4rnans signalsubstanser och CNS-st\u00f6rningar. Mesdopetam (IRL790), under utveckling f\u00f6r behandling av levodopa-inducerade dyskinesier, har slutf\u00f6rt Fas IIb och \u00e4r i f\u00f6rberedelse f\u00f6r Fas III. Pirepemat (IRL752), befinner sig f\u00f6r n\u00e4rvarande i Fas IIb, och utv\u00e4rderas f\u00f6r sin effekt p\u00e5 balans och fallfrekvens vid Parkinson. Dessutom utvecklar bolaget \u00e4ven de tre prekliniska programmen IRL757 (med finansiering fr\u00e5n Michael J. Fox Foundation), IRL942 och IRL1117 mot Fas I-studier. IRLAB:s pipeline har genererats av bolagets egenutvecklade systembiologibaserade forskningsplattform Integrative Screening Process (ISP). IRLAB har sitt huvudkontor i Sverige och \u00e4r noterat p\u00e5 Nasdaq Stockholm (IRLAB A). F\u00f6r mer information, bes\u00f6k\u00a0<a href=\"http:\/\/www.irlab.se\/\" rel=\"noopener\" target=\"_blank\">www.irlab.se<\/a>.<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-attachment mfn-attachment-general\">\n<p><strong class=\"mfn-heading-1\">Bifogade filer<\/strong><\/p>\n<hr \/>\n<p><a class=\"mfn-primary\" href=\"https:\/\/storage.mfn.se\/07e007bc-2334-429a-bc7d-33b7d6c37483\/irlab-arsredovisning-2023.pdf\" rel=\"noopener\" target=\"_blank\">IRLAB \u00c5rsredovisning 2023<\/a><br \/><a href=\"https:\/\/storage.mfn.se\/96c3af9e-dd7b-4d8f-be7c-0ed753d72394\/549300JAT34LHEI0DH60-2023-12-31-sv.zip\" rel=\"noopener\" target=\"_blank\">549300JAT34LHEI0DH60-2023-12-31-sv<\/a><br \/><a href=\"https:\/\/storage.mfn.se\/9abfc559-f894-417b-97ad-f998c5ae636c\/549300jat34lhei0dh60-2023-12-31-sv.xhtml\" rel=\"noopener\" target=\"_blank\">549300JAT34LHEI0DH60-2023-12-31-sv<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>G\u00f6teborg, den 29 april 2024 \u2013 IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), ett f\u00f6retag som uppt\u00e4cker och utvecklar nya behandlingar vid Parkinsons sjukdom, meddelade idag att bolagets \u00e5rsredovisning f\u00f6r 2023 finns tillg\u00e4nglig p\u00e5 bolags webbplats, www.irlab.se.<\/p>\n","protected":false},"template":"","class_list":["post-11480","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-report-annual_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-report_sv","mfn-news-tag-mfn-regulatory_sv","mfn-news-tag-mfn-lang-sv_sv","mfn-news-tag-mfn-regulatory-vpml_sv"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>IRLAB publicerar \u00e5rsredovisning f\u00f6r 2023 - IRLAB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/irlab.se\/sv\/mfn_news\/irlab-publicerar-arsredovisning-for-2023\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IRLAB publicerar \u00e5rsredovisning f\u00f6r 2023 - IRLAB\" \/>\n<meta property=\"og:description\" content=\"G\u00f6teborg, den 29 april 2024 \u2013 IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), ett f\u00f6retag som uppt\u00e4cker och utvecklar nya behandlingar vid Parkinsons sjukdom, meddelade idag att bolagets \u00e5rsredovisning f\u00f6r 2023 finns tillg\u00e4nglig p\u00e5 bolags webbplats, www.irlab.se.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/irlab.se\/sv\/mfn_news\/irlab-publicerar-arsredovisning-for-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"IRLAB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minuter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/irlab.se\/sv\/mfn_news\/irlab-publicerar-arsredovisning-for-2023\/\",\"url\":\"https:\/\/irlab.se\/sv\/mfn_news\/irlab-publicerar-arsredovisning-for-2023\/\",\"name\":\"IRLAB publicerar \u00e5rsredovisning f\u00f6r 2023 - IRLAB\",\"isPartOf\":{\"@id\":\"https:\/\/irlab.se\/#website\"},\"datePublished\":\"2024-04-29T17:30:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/irlab.se\/sv\/mfn_news\/irlab-publicerar-arsredovisning-for-2023\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/irlab.se\/sv\/mfn_news\/irlab-publicerar-arsredovisning-for-2023\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/irlab.se\/sv\/mfn_news\/irlab-publicerar-arsredovisning-for-2023\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/irlab.se\/sv\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\/\/irlab.se\/sv\/pressmeddelanden\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"IRLAB publicerar \u00e5rsredovisning f\u00f6r 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/irlab.se\/#website\",\"url\":\"https:\/\/irlab.se\/\",\"name\":\"Irlab\",\"description\":\"Novel treatments for Parkinson&#039;s disease\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/irlab.se\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IRLAB publicerar \u00e5rsredovisning f\u00f6r 2023 - IRLAB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/irlab.se\/sv\/mfn_news\/irlab-publicerar-arsredovisning-for-2023\/","og_locale":"sv_SE","og_type":"article","og_title":"IRLAB publicerar \u00e5rsredovisning f\u00f6r 2023 - IRLAB","og_description":"G\u00f6teborg, den 29 april 2024 \u2013 IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), ett f\u00f6retag som uppt\u00e4cker och utvecklar nya behandlingar vid Parkinsons sjukdom, meddelade idag att bolagets \u00e5rsredovisning f\u00f6r 2023 finns tillg\u00e4nglig p\u00e5 bolags webbplats, www.irlab.se.","og_url":"https:\/\/irlab.se\/sv\/mfn_news\/irlab-publicerar-arsredovisning-for-2023\/","og_site_name":"IRLAB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"2 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/irlab.se\/sv\/mfn_news\/irlab-publicerar-arsredovisning-for-2023\/","url":"https:\/\/irlab.se\/sv\/mfn_news\/irlab-publicerar-arsredovisning-for-2023\/","name":"IRLAB publicerar \u00e5rsredovisning f\u00f6r 2023 - IRLAB","isPartOf":{"@id":"https:\/\/irlab.se\/#website"},"datePublished":"2024-04-29T17:30:00+00:00","breadcrumb":{"@id":"https:\/\/irlab.se\/sv\/mfn_news\/irlab-publicerar-arsredovisning-for-2023\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/irlab.se\/sv\/mfn_news\/irlab-publicerar-arsredovisning-for-2023\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/irlab.se\/sv\/mfn_news\/irlab-publicerar-arsredovisning-for-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/irlab.se\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/irlab.se\/sv\/pressmeddelanden\/"},{"@type":"ListItem","position":3,"name":"IRLAB publicerar \u00e5rsredovisning f\u00f6r 2023"}]},{"@type":"WebSite","@id":"https:\/\/irlab.se\/#website","url":"https:\/\/irlab.se\/","name":"Irlab","description":"Novel treatments for Parkinson&#039;s disease","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/irlab.se\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"}]}},"_links":{"self":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/mfn_news\/11480","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/media?parent=11480"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}